Description

Novartis Buyout Of Myricx Raises A $1.5 Billion Question!

Novartis has put another marker down in oncology, agreeing to buy U.K.-based Myricx Bio for up to $1.5 billion. The proposed deal includes $1.1 billion upfront and up to $400 million in milestone payments, with closing expected in the second half of 2026. Myricx is still preclinical, yet its antibody-drug conjugate platform offers differentiated cancer-killing mechanisms aimed directly at tumor cells. That mix of early science and a large upfront check has drawn attention, especially because Novartis is already leaning on oncology growth from Kisqali, Pluvicto, and Scemblix. At the same time, management is navigating generic erosion, higher R&D spending, and a busy bolt-on M&A agenda after Avidity. The Myricx move fits that playbook: pay early for optionality, then use scale to test whether the platform can matter clinically. It is a small deal for Novartis, but not a low-risk one. That is why the synergies deserve scrutiny now.